The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said substituted benzene disulfonamides are binding to the prenyl binding pocket of PDE6 and therefore, are useful for the prophylaxis and treatment of cancer by inhibition of the binding of PDE6 to farnesylated Ras proteins and thereby, inhibition of oncogenic Ras signaling in cells.

Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

The present invention directs to provide a novel compound for treating and/or preventing pain, having excellent skin permeation and reduced skin irritation. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof (R.sup.1: a methyl group or other like group, R.sup.2: a fluorine atom or other like group, R.sup.3: a methyl group or other like group, R.sup.4: a methyl group or other like group, R.sup.5: a methyl group or other like group)

##STR00001##

The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): ##STR00001##
comprising treating a compound of Formula (I): ##STR00002##
with a transition metal catalyst and under alkylation conditions as valence and stability permit.

The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): ##STR00001##
comprising treating a compound of Formula (I): ##STR00002##
with a transition metal catalyst and under alkylation conditions as valence and stability permit.

The present invention provides a compound represented by formula (i), a liquid crystal composition using the compound, and a liquid crystal display device using the liquid crystal composition. The compound represented by formula (i) has a partial structure K.sup.i1 represented by any of general formulas (K-1) to (K-17) and further has ring B having at least two P-Sp- groups. Therefore, when used for a liquid crystal composition, the compound adsorbs to substrates sandwiching the liquid crystal composition (liquid crystal layer) and allows liquid crystal molecules to be held such that they are aligned in a vertical direction without a PI layer, and improved alignment stability and low-temperature storage stability can be achieved.

The present invention provides a compound represented by formula (i), a liquid crystal composition using the compound, and a liquid crystal display device using the liquid crystal composition. The compound represented by formula (i) has a partial structure K.sup.i1 represented by any of general formulas (K-1) to (K-17) and further has ring B having at least two P-Sp- groups. Therefore, when used for a liquid crystal composition, the compound adsorbs to substrates sandwiching the liquid crystal composition (liquid crystal layer) and allows liquid crystal molecules to be held such that they are aligned in a vertical direction without a PI layer, and improved alignment stability and low-temperature storage stability can be achieved.

Disclosed are compounds of formulae:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.

Disclosed are compounds of formulae:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.